A multifunctional nanotheranostic agent potentiates erlotinib to EGFR wild-type non-small cell lung cancer

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI), such as Erlotinib, have demonstrated remarkable efficacy in the treatment of non-small cell lung cancer (NSCLC) patients with mutated EGFR. However, the efficacy of EGFR-TKIs in wild-type (wt) EGFR tumours has been shown to be...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Duo, Zhou, Jun, Fang, Weimin, Huang, Cuiqing, Chen, Zerong, Fan, Meng, Zhang, Ming-Rong, Xiao, Zeyu, Hu, Kuan, Luo, Liangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844835/
https://www.ncbi.nlm.nih.gov/pubmed/35224311
http://dx.doi.org/10.1016/j.bioactmat.2021.10.046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8844835/
https://www.ncbi.nlm.nih.gov/pubmed/35224311
http://dx.doi.org/10.1016/j.bioactmat.2021.10.046

Ejemplares similares